CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Umbilical cord derived mesenchymal stem cellsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2122 Placebo Wiki 0.05

Correlated MeSH Terms (5)

Name (Synonyms) Correlation
D013313 Stress Disorders, Post-Traumatic NIH 0.18
D016638 Critical Illness NIH 0.13
D011014 Pneumonia NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials

1 Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19

The disease caused by the new coronavirus, SARS-CoV-2, called COVID-19, it has considered a worldwide pandemia by the WHO. Suddently, it produces a lot of patients severe ill, in a little geographic area, that could surpase the resourses of the any health system in the world. There is no documentation of an effective alternative for the treatment of the severe ill patients, that can reduce the mortality or the adverse events suffered by these people. It is has suggested the usefulness of the Mesenchymal Stem cells (MSC) for the management of these patients, thanks to their direct and indirect antiviral capacity, and its potency as immunomodulator, that could ameliorate the lung disease and the severity of COVID-19.

NCT04429763 COVID-19 Biological: Umbilical cord derived mesenchymal stem cells Biological: Placebo

Primary Outcomes

Description: Change in two or more degrees in the NEWS scale

Measure: Clinical deterioration or death

Time: 4 weeks

No related HPO nodes (Using clinical trials)